Skip to main content

Table 2 Plasma biomarker concentrations

From: Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer in symptomatic women

Biomarker

 

Normal Control (n = 244)

Benign

(n = 223)

Borderline

(n = 53)

Early Stage Malignant (Stages I & II) (n = 69)

Late Stage Malignant (Stages III & IV)

(n = 120)

CA-125

Mean ± SE

6.05 ± 10.4

27.35 ± 10.2

180.3 ± 137

380.9 ± 97

1337.0 ± 420

(U/mL)

Median (range)

4.10 (0.5-146)a

7.60 (0.5-2219)a

13.1 (1.2-7266)a, b

52.3 (0.5-4277)a, b

208.5 (3.3-47206)a, b

CRP

Mean ± SE

3.99 ± 0.7

8.20 ± 1.5

10.05 ± 3.6

16.73 ± 3.4

39.65 ± 4.5

(mg/L)

Median (range)

1.38 (0.08-149.4)

1.81 (0.08-172.7)

3.09 (0.17-186.7)

4.77 (0.10-139.1)a, b

21.80 (0.30-309.5)a, b

SAA

Mean ± SE

10.82 ± 2.5

29.00 ± 7.9

22.11 ± 11.3

47.47 ± 13.3

127.7 ± 24.3

(mg/L)

Median (range)

4.34 (0.77-489.0)

4.95 (0.80-1337)

4.74 (1.20-593.2)

8.50 (1.00-737.0)a, b

24.23 (0.96-1958)a, b

IL-6

Mean ± SE

2.11 ± 0.23

2.61 ± 0.25

6.26 ± 2.79

8.54 ± 1.71

20.09 ± 6.29

(pg/ml)

Median (range)

1.00 (1.00-38.50)

1.00 (1.00-29.50)

1.00 (1.00-146.0)

4.10 (1.00-93.70)a, b

8.45 (1.00-628.0)a, b

IL-8

Mean ± SE

3.73 ± 0.33

10.27 ± 1.81

16.83 ± 5.67

19.27 ± 4.88

29.36 ± 5.88

(pg/mL)

Median (range)

2.50 (2.50-58.70)

2.50 (2.50-292.0)a

2.50 (2.50-183.0)a

2.50 (2.50-239.0)a, b

6.10 (2.50-408.0)a, b

  1. Data are presented as mean ± SE and median (range). a: p < 0.05 compared with normal controls and b: p < 0.05 compared with benign group (Kruskal-Wallis followed by Dunn's Multiple Comparison test). Note that 33 malignant ovarian cancer samples were excluded from early/late stage analysis since stage data was not recorded.